Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Myelodysplastic Syndromes 6Leukemia, Myeloid, Acute 6Leukemia 6Hodgkin Disease 6Lymphoma 5Multiple Myeloma 4Anemia, Refractory, with Excess of Blasts 4Lymphoma, Non-Hodgkin 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma, Follicular 3Leukemia, Myelomonocytic, Chronic 3Leukemia, Myeloid, Chronic-Phase 3Leukemia, Myeloid, Accelerated Phase 3Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Leukemia, Lymphocytic, Chronic, B-Cell 3Myeloproliferative Disorders 2Lymphoma, Mantle-Cell 2Lymphoma, Large-Cell, Immunoblastic 2Graft vs Host Disease 2Congenital Abnormalities 2Burkitt Lymphoma 2Waldenstrom Macroglobulinemia 1Thrombocythemia, Essential 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Recurrence 1Primary Myelofibrosis 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1

Interventions

Specimen Handling 3Nivolumab 3Ipilimumab 3Biopsy 3prednylidene 2pembrolizumab 2deltacortene 2Prednisone 2Magnetic Resonance Spectroscopy 2CTLA-4 Antigen 2talimogene laherparepvec 1oblimersen 1cixutumumab 1avelumab 1antineoplaston AS 2-1 1antineoplaston A10 1Tacrolimus 1Sirolimus 1Salts 1Radiosurgery 1Octreotide 1Imatinib Mesylate 1Everolimus 1Complementary Therapies 1Biological Therapy 1Acetates 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Carcinoma, Merkel Cell × Tacrolimus × Clear all
NCT03816332 2026-04-30

Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers

National Cancer Institute (NCI)

Phase 1 Active not recruiting
12 enrolled 13 charts
Dermatologic

Carcinoma, Basal Cell, Melanoma, Carcinoma, Merkel Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡